Object. The discovery of incidental low-grade gliomas (LGGs) on MR imaging is rare, and currently there is no existing protocol for management of these lesions. Various studies have approached the dilemma of managing patients with incidental LGGs. While some advocate surgery and radiotherapy, others reserve surgery until there is radiological evidence of growth. For neurosurgeons and radiologists, determining the course of action after routine brain imaging poses not only a medical but also an ethical dilemma. The authors conducted a systematic review of case reports and case series in hopes of enhancing the current understanding of the management options for these rare lesions.
I
ncIdental abnormal findings on MR imaging are occasionally noted in asymptomatic individuals. In the case of LGGs, the reported occurrence of incidental findings is extremely rare, with an incidence rate of 0.04%-0.2% within the general asymptomatic population. 19, 26 Although seizures are often the presenting symptoms in most LGGs, incidental LGGs lack associated specific symptoms and remain undetected until the patient obtains radiological imaging for an unrelated reason. The majority of incidental findings are a consequence of general radiological screening of an asymptomatic population;
26 they may also be discovered as a result of imaging for trauma 34 or from investigation of other neurological or nonspecific conditions. 38 With the increasing use of MR imaging of the brain by clinicians and investigators, the occurrence of these incidental findings has increased. 17, 20, 23, 24 Typically, the objective of preventative screening using CNS imaging is to identify any abnormalities that may pose significant future risk. For gliomas in particular, the goal is early identification and intervention before anaplastic dedifferentiation to potentially thwart progression and improve survival. Patients with incidental gliomas may have longer overall survival from radiological diagnosis than patients with symptomatic gliomas. 29 Incidental gliomas potentially represent an early step in the histopathologiThe management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm cal progression of high-grade gliomas. 8 Detecting and treating incidental gliomas may therefore yield a better prognosis, limiting active treatment to symptomatic gliomas; however, no long-term prospective analysis has been conducted to provide confirmation.
On the other hand, several studies have questioned the validity of glioma screening. According to Steiger, 37 screening for gliomas is unjustified given their rarity and the lack of evidence corroborating the prognostic value of early intervention. In addition, long-term studies hint at the inevitability of glioma progression even with early diagnosis and treatment. 35 Because of the ubiquity of brain imaging for a wide variety of unrelated complaints, the occurrence of incidental LGG is likely to continue to increase, furthering the need for an appropriate management paradigm for these lesions.
Various studies have approached the dilemma of managing patients with incidental LGG. Although some studies advocate surgery and radiotherapy, other studies suggest that deferral of surgery until tumor progression may be more appropriate for asymptomatic patients. For neurosurgeons and radiologists, determining the course of action after routine brain imaging poses not only a medical but also an ethical dilemma. On the one hand, surgical intervention carries the risk of harm without benefit in terms of symptomatic relief; on the other hand, passively allowing tumor progression carries the potential for preventable harm. These questions have been only rarely addressed in the literature on this topic. 17 In this paper, we analyze all relevant published data on the management of incidental LGGs and determine whether there is a consensus on their management.
Methods

Study Selection
Our study used the MeSH database system within the PubMed search engine to perform our literature search. Within the MeSH system, we searched between 1990 and 2011 for the phrases "incidental findings" and "glioma." Because of the low number of matches, we expanded our search to a general PubMed search of the following phrases singly: "incidental astrocytoma," "incidental oligodendroglioma," "asymptomatic astrocytoma," and "asymptomatic oligodendroglioma." To ensure that all possible studies were included, another PubMed search was conducted using the terms "magnetic resonance imaging AND (incidental finding* OR incidental discover* AND brain)." Articles were limited to those in English, and humans were defined as the subjects for this study.
To examine the controversial management issues of gliomas, we limited our study to the main spectrum of incidental LGGs: low-grade (WHO Grade I or II) astrocytomas and oligodendrogliomas. To meet the inclusion criteria for this paper, each article must have had at least 1 case of an incidental/asymptomatic LGG (astrocytoma or oligodendroglioma) found based on MR imaging. Case reports and large asymptomatic screenings were included, and editorials and commentaries were excluded. Articles that did not describe methods of treatment/management for the incidental tumor were excluded. No studies were found to be duplicates. The last search was performed July 1, 2011.
Data Extraction
The included studies were carefully analyzed based on the patient population, methodology, reasoning for MR imaging, treatment modality, outcome, and follow-up time. Articles were separated into 2 main groups based on treatment: active surveillance and surgical treatment. Included in the surgery group were patients who underwent surgery or biopsies, including patients who delayed treatment until symptomatic progression. Patients who waited until malignant transformation for treatment were placed in the surgical group. Patients who were originally diagnosed with incidental LGG but were found to have malignant tumors were excluded. The outcome of these patients was reported in reference to the author's postoperative outcome and follow-up description.
Data for all patients were reported when available in the literature. We note that the literature search yielded very few articles, and from those articles, only a few contained full data sets for our study. No formal statistical analysis was performed due to the small sample size and intrinsic selection bias.
Results
Study Selection
Six case series (4 retrospective analyses and 2 prospective studies) and 3 case reports met the criteria for our study (Table 1) . Seventy-two patients were included, with a mean age of 37.0 years (range 3-63 years). The maleto-female ratio was 0.68. Two papers formed the majority of cases with 17 11 and 47 29 patients, comprising 88.9% of the total study population. Within specific papers, certain patient data sets with incidental LGG were excluded because the reported information was pooled with other patient populations, and management information specific to patients with incidental LGG was not specified. 27 In addition, cases involving findings of incidental LGG with CT scans were not included due to the lack of diagnostic certainty (gliomas may be isodense on CT) and the implausibility of using CT scans in asymptomatic research studies due to radiation risks. 6, 9, 10, 30, 31 Four cases that were originally believed to be incidental LGG (based on radiological evidence) were excluded because histological examination revealed malignant WHO Grade III and IV astrocytomas.
11 Incidental LGG was most often diagnosed due to investigation of nonspecific or unrelated symptoms (69.4%), through workup of concurrent CNS lesions (13.9%), through MR imaging screening of healthy volunteers (11.1%), and following trauma (5.6%). The most common presenting symptom was headache (50%), followed by dizziness (22%) and mood disorders (8%; Table  2 ). Other reported nonspecific or unrelated symptoms included amenorrhea (6%), blurred vision (4%), fainting (4%), hearing deficiencies (4%), and lower-limb paresthesias (2%). All nonspecific or unrelated symptoms were not found to be related to the functional location of the incidental LGG. The 10 symptomatic lesions diagnosed that led to the discovery of an incidental LGG were additional symptomatic gliomas (2), schwannomas (2), meningioma (1), pituitary adenoma (1), arteriovenous malformation (1), cerebellar atrophy (1), SAH of the anterior communicating artery (1), and surveillance imaging of a postoperative Chiari malformation (1).
Reasons for Treatment
Within the study group, 4 patients (5.6%) did not mention a reason for treatment distinct from the standard of protocol for LGGs and were treated immediately. For the rest of the patients (Table 3) , reasons for treatment included 24 of the 56 patients with radiological evidence of growth (42.9%), 15 with manifestations of physical symptoms (26.8%), 8 with radiological evidence of malignant transformation (14.3%), 4 with the need for histological diagnosis (7.1%), and 1 with patchy enhancement (1.8%). Two reports measured the volumetric diameter expansion with MR imaging and determined the necessity of treatment based on models of predicted LGG growth of 3.5 mm per year. 8, 29 Another study used 18 F-FET PET analysis in conjunction with MR imaging to determine the prognosis of incidental LGG and subsequent treatment.
11 If there was radiological evidence of continuous slow growth (2-3 mm per year) and a negative 18 F-FET PET scan, patients were referred to surgery, and histological confirmation was performed. Included in the patients who were treated as a result of physical symptoms was a case of symptomatic SAH anatomically close to an incidental LGG in the frontal lobe, which facilitated tumor removal with a single craniotomy. 38 Eight patients underwent biopsies, which revealed incidental LGGs, but these patients refused further treatment after histological diagnosis until MR imaging demonstrated a suspected malignant transformation.
Patient Management
Patients were divided into 2 categories: those who underwent resection/biopsies and those who did not. In the surgery category, 56 patients were treated at a mean of 21.4 months (range 0-171 months) after radiological diagnosis. At least partial resection was achieved in 40 patients (71.4%), with 16 undergoing biopsy only (28.6%; Table 4 ). Fourteen patients delayed surgery until evidence of physical symptoms and were treated similarly to standard LGG patients (with resection). One patient with an SAH from a ruptured anterior communicating artery aneurysm in the same anatomical location as a glioma was treated surgically by a single craniotomy.
Stereotactic biopsies were obtained prior to treatment in 16 patients (Table 4) . 29 Of these 16 patients, 8 did not receive oncological treatment until malignant transformation, whereas 1 received radiotherapy and 5 received chemotherapy. The mode of treatment was unspecified in the 8 patients who had radiological evidence of malignant transformation and in 2 patients who received a stereotactic biopsy alone because of pooling of information within the article. Histological confirmation was made by either stereotactic biopsy primarily (16 patients) or surgical removal (40 patients; Table 5 ). A total of 16 patients underwent active surveillance after radiological diagnosis of incidental LGG, without histological confirmation. Fifteen patients demonstrated negative results on the study's prognostic tests (negative growth on serial MR imaging and negative 18 F-FET PET scan), so no treatment was required. These patients underwent clinical and radiological follow-up examinations. In 1 case a patient was referred to a tertiary center where treatment was believed to be unwarranted.
39
Outcomes
The mean follow-up among all 72 patients was 74.8 months (range 0-29.7 years; data available for 69 patients). Outcomes were reported for the surgical group and the active surveillance group. Within the surgical group of 56 patients, 49% did not have any neurological deficits and remained stable with no events over the course of the followup period (Fig. 1) . Twenty-five percent of the patients in the surgical group had radiological or histological confirmation of tumor progression to a higher WHO grade (mean follow-up postdiscovery using radiology was 5.4 years). This also included 8 patients who waited for oncological treatment until malignant transformation. Approximately 13% of the surgical group underwent a second treatment, and 7% died during the course of follow-up.
The outcome of 10 patients was complicated by the existence of other symptomatic lesions and tumors that were diagnosed simultaneously to the incidental LGG. Individual survival rates for this specific patient population were not calculable because several papers reported grouped data instead of individual data sets. In fact, 80% of the symptomatic lesions that justified an initial radiological screening were from a single paper, which also had the highest reported complication rates. 29 It is likely that the patients with coexisting symptomatic lesions and incidental LGGs may have had worse outcomes, although individual data were not reported in any included study.
Asymptomatic patients from large screening trials without previous surgery or neurological impairment who underwent surgery did not have any reported complications. 19, 28 Among the patients whose incidental LGGs were discovered due to trauma, there were no reported recurrences, and only 1 patient with a tectal glioma had a KPS score < 100 at follow-up.
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Among the 16 patients with no interventional treatment, radiological evidence of lesion regression (at least 30% of original diameter) occurred in 5 patients; in 4 of these patients the lesion completely resolved within 6 months, and 1 slowly regressed over 1 year. For patients with lesion regression, clinical and radiological examinations with MR imaging were performed at 4-month intervals for 1-2 years after radiological diagnosis. 11 Ten patients did not demonstrate any growth and remained stable during the course of follow-up examinations for 3 years. The MR imaging findings of these patients were inconclusive, although they suggested the presence of an incidental LGG. Both those with lesion regression and those with stable lesions had negative prognostic indicators of malignancy, with negative 18 F-FET PET scans and no growth on MR imaging. No complications were reported for this patient population, although Floeth et al.
11
mentioned the possibility that a thromboembolic event may have been attributable to a radiological lesion in 1 patient. There was no evidence of poor outcomes at follow-up for the untreated patients (Fig. 2 ). 
Fig. 1. Management outcomes of patients with incidental
LGG in the surgical group. This group includes patients who delayed surgery until radiological progression and/or clinical manifestations.
Fig. 2. Management outcomes of patients with incidental
LGG in the active surveillance group. This group includes patients who were determined to have incidental LGG based on radiological findings alone. Follow-up MR imaging found no tumor growth and showed negative 18 F-FET PET uptake in 15 patients.
Discussion
Incidental LGGs account for roughly 3%-5% of all LGGs. 1, 18 As neuroimaging technology advances and thus incidence increases, the controversial issues surrounding treatment of incidental findings will become increasingly relevant. This holds true for incidental LGG, as well as many other radiological findings of incidental pathology elsewhere in the body. Although some authors propose a uniform policy toward managing incidental findings, 3 many investigators do not comment on management options and usually adhere to a similar approach to that applied to symptomatic patients. 34 Because of these discrepancies in the management of these lesions, and even in the recognition of incidental LGG as a distinct entity, understanding the natural history and response to treatment of these lesions is extremely important.
Symptomatic Versus Incidental LGG: Is There a Difference?
Duffau and colleagues 8 proposed that incidental LGG may be an earlier step in the pathological progression of LGG. Their data extrapolated the genesis of a Grade II glioma using repeated surveillance MR images of a 31-year-old patient after decompression for a Chiari malformation. Using these repeat scans, the volumetric diameter expansion was established, dating the inception of the glioma and providing critical insight into the pathogenesis of LGG. Pallud et al. 29 provided supplemental data to distinguish between the traditional symptomatic LGG and incidental LGG. The incidental 47 patients in the LGG group in this study had a lower age at diagnosis, a significantly smaller tumor volume, and a significantly lower rate of midline shift at the time of radiological diagnosis, which gives credence to the theory that incidental LGG may represent a premature step in the natural course of LGG. In addition, 13 patients developed clinical symptoms when no treatment was initiated. Of significance, the study also reported an increased survival rate among the incidental LGG group, although this may be attributable to lead-time bias from early diagnosis. The question of whether survival is affected by early treatment of incidental LGG is, as yet, unanswered.
Does the Mode of Discovery of Incidental LGG Matter?
Within our study, incidental LGGs were discovered due to a variety of reasons including research studies, nonspecific symptoms, trauma, and other symptomatic lesions. There are 2 categories of patients that must be considered fundamentally differently based on the ethical considerations of further investigation and treatment. The first is the group of healthy, asymptomatic volunteers among whom incidental LGG is discovered through participation in a research study or preventative screening program. The second is the group of patients who receive MR imaging for other neurological or nonspecific complaints. The treatment approach to these 2 groups is fundamentally different, as outlined below.
Healthy Volunteers. Studies with healthy volunteers comprised 11.1% of our review's patient population. Although not the majority of patients, intervention in this group is controversial. Because many healthy volunteers are enrolled in brain MR imaging screenings, occasionally for research or for occupational screening, the protocols that govern treatment and management of these lesions should be defined clearly. 15, 16, 39, 40 Due to the potential impact on quality of life and occupation from a diagnosis of glioma, the following questions should be explicitly addressed prior to enrolling patients in research studies that carry the potential for revealing an incidental LGG: 1) is the patient fully aware of the potential implications of brain MR imaging and the possibility of an incidental finding; 2) who should supervise the follow-up care for these patients in the event that an incidental LGG is found; 3) who will provide the neurosurgical care for these patients; and 4) what is the accepted guideline for treating a lesion that produces no clinical symptoms?
Floeth et al. 11 outlined a potential treatment paradigm for patients enrolled as healthy volunteers who are radiologically diagnosed with incidental LGG, with active surveillance by MR imaging every 3-4 months with a concurrent PET scan (used to discover possible malignant gliomas). Pallud et al. 29 followed a similar regimen without the addition of the PET scan. Most of the patients in this study underwent oncological treatment after radiological progression with few receiving treatment due to patchy enhancement on MR imaging or the need to confirm histology. In this manner, exploratory surgery may be avoided and additional MR imaging investigation can be used to confirm growth by volumetric diameter expansion. However, once symptomatic progression occurs or radiological evidence of growth or malignant transformation is found, the need for resection becomes more pressing. In cases in which a needle biopsy has been performed and histology confirms an incidental LGG, the optimal management approach remains to be elucidated.
Nonspecific or Unrelated Symptoms. There may be considerable debate as to whether a particular patient's symptoms are, in fact, related to the incidental LGG. Although symptoms such as headaches, mood disorders, and amenorrhea may not be functionally related to incidental LGG, the correlation between presentation and pathology can be difficult to attribute to coincidence alone. 12, 25 In these cases, the patient's preferences are instrumental in guiding therapeutic decisions. In general, management in these patients tends to be more aggressive due to the uncertain cause of their symptoms; 29 however, as before, radiological evidence of growth before initiation of treatment can be a prerequisite for any intervention. In the study by Floeth et al.,
11 most (14/15) of the patients with nonspecific symptoms did not show any radiological evidence of growth, and treatment was avoided. At the end of the follow-up period, patients remained healthy and had no evidence of seizures. Nevertheless, these patients remain challenging to manage because their symptomatology is unclear, and the definite need for surgery is yet to be established. For any patient who desires surgical intervention for resection of an incidental LGG in the setting of vague or not functionally related symptoms, the risk that surgery will not relieve their chief complaint must be explicitly and carefully outlined.
Incidental LGG in Patients With Concurrent CNS
Disease. In the few cases in which symptomatic CNS lesions were the main reason for radiological imaging, management of a coincidental incidental LGG can be difficult. In the 10 cases reported in the analyzable literature, resection was performed in all cases; however, the justification for surgery has not always been readily apparent. 29 The decision to perform a biopsy/resection may be justified in this population due to increased morbidity associated with multiple lesions, although there is no specific evidence for this in the published literature. Furthermore, the clinical decision to operate in these cases may be influenced by the neurosurgical protocol for treatment of the symptomatic lesion. For example, if a meningioma necessitates surgical intervention, it may be prudent to resect a nearby incidental LGG in the same surgery. 5, 7, 13 Age-Dependent Classification When determining treatment for incidental LGG, the neurosurgeon may be compelled to alter his or her decisions based on the age of the patient at diagnosis. For example, younger patients may be more prone to receive surgery earlier due to parent's anxiety of "observing" children with incidental LGG. Furthermore, for the middle-age group of patients, surgery may be a viable option given no previous history of comorbidities. Considering evidence of an age-dependent increase in anaplastic transformation of incidental LGG, operative decisions may be made depending on the age of the patient at diagnosis. 4, 32, 33 For example, studies by Shafqat et al. 33 demonstrated that patients older than 45 years of age have a mean time to dedifferentiation of 7.5 months after radiological diagnosis, compared with 44.2 months in patients younger than 45 years. However, the elderly population may benefit from active observation given that neurosurgery on elderly patients may have an increased risk for complications and poor outcomes. Regardless, age must be factored together with the mode of discovery and other confounding factors into the decision for treatment of incidental LGG.
Treatment Paradigm. The management of incidental LGG may be portrayed as a continuum of care due to the interplay between the active surveillance group and the surgical group. Many patients (24) in the surgical group initially were actively observed and underwent resection at a later time. Therefore, understanding the transition between active surveillance and surgery may be an important tool in creating a treatment paradigm. Based on our review of analyzable literature, we have established the safety of active surveillance, and have therefore proposed the following diagram (Fig. 3) illustrating the management of incidental LGG.
Limitations. This interpretation of the literature on the topic of incidental LGG is subject to a number of limitations. Taken together, the case series and case reports of incidental LGG comprise Level III evidence and should not be used as a definitive guide for clinical practice, but rather as an indication of the viability of different treatment approaches for different patients.
The surgical group was the only group that reported negative outcomes. Although surgery is associated with inherent risks, there may be other risks attributable to the active surveillance group. Patients who are being observed without treatment may progress to anaplastic transformation or present with clinical symptoms, which could increase the overall morbidity and mortality in this group. However, because these patients may eventually receive some form of treatment, they transition to the surgical group. Therefore, a portion of the surgical group may be a reflection of an acute cohort of the active surveillance group. Because all the patients underwent biopsies/surgeries (retrospectively screened for incidental LGG confirmed by histology), it was difficult to eliminate this paper's negative outcome bias within the surgical group. Regardless, the outcomes of the surgical patients included deceased patients, the need for second treatment, and tumor progression (Fig. 1) . It is important to note that 8 patients diagnosed with radiological or histological evidence of tumor progression only underwent biopsy and were not fully treated until malignant transformation. Excluding the paper by Pallud et al., 29 it appears that the surgical group did not have many complications and that resection for incidental LGG remains relatively safe, although there may be a publication bias that excludes negative outcomes. In addition, suspected cases of incidental LGG that underwent resection that confirmed a different unsuspected lesion were not included in this study; therefore, it remains unknown how many diagnostically erroneous surgeries are performed.
Among the active surveillance group, incidental LGG was only suspected and not definitively diagnosed. This makes direct comparison between the 2 groups impossible, and outcomes should be used as a guide only rather than a definitive comparison for statistical analyses. Nevertheless, patients in this group who have been reported in the literature had extremely good outcomes, with no evidence of growth, malignant transformation, or clinical symptomatology. The majority of lesions remained stable throughout follow-up and demonstrated no growth on MR imaging.
It is important to recognize that although this paper provides insight into the management of incidental LGG, the authors of this paper are not offering evidence that supports the use of asymptomatic healthy patient screenings. Previously, it has been shown that these screenings can lead to misdiagnosis of patients with no underlying pathology, 2 increasing anxiety in patients by unmasking abnormalities that are not clinically relevant, 14, 22 or giving patients the false impression that their brain MR imaging is negative. Previous publications have provided insight into the necessity to tailor brain MR imaging for asymptomatic patients in specific at-risk populations instead of generalized screenings. 21 Patients at risk for cerebrovascular disease might benefit from brain imaging that could possibly identify asymptomatic cerebral infarctions and reduce future risk. However, for patients not at risk or enrolled in healthy volunteer research studies, the need for brain MR imaging screenings may not be clinically worthwhile as it would exaggerate negligible findings with very few clinically significant diagnoses.
Ethical Issues. The decision to treat patients without symptomatology is certainly an ethical predicament. In the case of incidental LGG, decisions to operate or intervene must be weighed with a careful examination of the clinical symptoms, history, and radiological findings. Without sufficient evidence, intervening in cases of incidental LGG may have significant ethical implications because it is unclear whether the decision to treat earlier improves overall survival rates. Also, surgical intervention must be weighed against the uncertainty of diagnosis, inadequate clinical history, or evidence of growth. In addition, intervening in suspected incidental LGG cases that do not necessitate immediate removal may disrupt the quality of life of asymptomatic patients or create increased pre-and postoperative anxiety, yet the decision not to operate can also be viewed as an ethical dilemma as well. Patients may not understand the rationale for withholding treatment until sufficient evidence is uncovered, and the neurosurgeon must be prepared to address all possible concerns about management in these cases. In all circumstances, precise care must be taken to maintain physician's values while respecting the patient's wishes.
Decisions to manage incidental LGG nonoperatively hold considerable legal implications in countries in which malpractice litigation is prevalent. Justifying active surveillance on a patient may result in increased litigation if there is sufficient evidence to demonstrate negligence. Currently, neurosurgeons must practice defensively in countries where medical malpractice lawsuits are prevalent, and considerable precaution must be taken into account before a decision to not operate is made. In other countries with more malpractice reform, nonsurgical intervention may be facilitated.
Conclusions
For the neurosurgeons responsible for the care of patients with incidental LGG, understanding the ethical responsibilities of treating asymptomatic lesions is critical as we address this problem in the future. Urgent surgery is not always indicated in cases of suspected incidental LGG, and each patient's treatment must be individualized based on the context, circumstances, and characteristics of the diagnosed lesion. Recognizing that incidental LGG is a precursor to symptomatic LGG may just be the first step in the process of elucidating a unified therapeutic approach for these lesions. Based on the continuum between surveillance and treatment, our treatment paradigm may be clinically useful in asymptomatic patients; however, these decisions for an incidental LGG in settings of concurrent lesions may be different. It is likely that serial clinical examination and MR imaging is a safe option for most asymptomatic patients, with the option of intervention based on certain criteria that are, as yet, to be elucidated fully.
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